Showing 3691-3700 of 5693 results for "".
- Cencora Acquires Retina Consultants of Americahttps://modernod.com/news/cencora-advances-specialty-leadership-through-acquisition-of-retina-consultants-of-america/2482528/Contract research organization Cencora has entered into a definitive agreement to acquire Retina Consultants of America (RCA), a management services organization (MSO) of retina specialists, from Webster Equity Partners. Cencora, formerly known as AmerisourceBergen, will acquire RC
- New Report by Contact Lens Institute Reveals Strategies to Enhance Contact Lens Retentionhttps://modernod.com/news/new-report-by-contact-lens-institute-reveals-strategies-to-enhance-contact-lens-retention/2482520/The Contact Lens Institute (CLI) has just published an in-depth, data-driven report titled “Disrupting the Dropout Dilemma: Practical Steps to Keep Patients in Contact Lenses.” Aimed at assisting eye care
- Corxel and Lenz Therapeutics Announce Positive Phase 3 Trial Results for Presbyopia Eye Drop LNZ100 in Chinahttps://modernod.com/news/corxel-pharmaceuticals-and-lenz-therapeutics-announce-positive-phase-3-trial-results-for-presbyopia-eye-drop-lnz100-in-china/2482519/Lenz Therapeutics and its parner Corxel Pharmaceuticals unveiled phase 3 trial results from the China-based JX07001 study, showing that LNZ100, an aceclidine-based eye drop, achieved significant improvement in near vision for presbyopia patients. The study's topline results demonstr
- Astellas Withdraws European Application for Avacincaptad Pegol for GAhttps://modernod.com/news/astellas-withdraws-european-application-for-investigational-geographic-atrophy-treatment/2482517/Astellas Pharma announced it is withdrawing its marketing authorization application for avacincaptad pegol (ACP) from the European Medicines Agency (EMA). ACP, an investigational intravitreal treatment designed to inhibit the complement C5 protein, was developed for geographic atrophy (
- EyePoint Pharma Announces Positive Interim Results for Duravyu in Phase 2 VERONA Trial for DMEhttps://modernod.com/news/eyepoint-pharma-announces-positive-interim-results-for-duravyu-in-phase-2-verona-trial-for-dme/2482516/EyePoint Pharmaceuticals reported interim 16-week data from its ongoing phase 2 VERONA clinical trial, which is assessing the investigational sustained delivery therapy Duravyu. The therapy, developed for patients with diabetic macular edema (DME), leverages a proprietary bioerodible Duraser
- EyePoint Pharmaceuticals Doses First Patient in Phase 3 LUGANO Trial for Wet AMD Therapy Duravyuhttps://modernod.com/news/eyepoint-pharmaceuticals-doses-first-patient-in-phase-3-lugano-trial-for-wet-amd-therapy-duravyu/2482512/EyePoint Pharmaceuticals announced dosing of the first patient in its phase 3 LUGANO clinical trial of Duravyu. This investigational sustained delivery therapy, formerly known as EYP-1901, aims to treat wet age-related macular degeneration (AMD) using a patent-protected formulation of vorolanib,
- Science Corporation: PRIMA Clinical Trials Show Restoration of "Form Vision"https://modernod.com/news/science-corporation-announces-breakthrough-in-retinal-implant-technology-prima-clinical-trials-show-restoration-of-form-vision/2482509/Science Corporation, a developer in brain-computer interface (BCI) technology, has announced preliminary results from clinical trials of its PRIMA retina implant. This technology has demonstrated the ability to restore what the company is calling 'form vision' in patients suffer
- Ocuphire Acquires Gene Therapy Company Opus Geneticshttps://modernod.com/news/ocuphire-acquires-gene-therapy-company-opus-genetics/2482508/Ocuphire Pharma announced an all-stock acquisition of Opus Genetics, a clinical-stage gene therapy company specializing in inherited retinal diseases (IRDs). As part of the deal, the combined company will be renamed Opus Genetics, effective October 23, 2024, and will begin trading under the
- Cathleen McCabe, MD, Appointed Strategic Medical Advisor at Bausch + Lombhttps://modernod.com/news/cathleen-mccabe-md-appointed-strategic-medical-advisor-at-bausch-lomb/2482507/Bausch + Lomb has appointed Cathleen McCabe, MD, as Strategic Medical Advisor. According to B+L, in this new consultancy role, Dr. McCabe will contribute her expertise to Bausch + Lomb’s product portfolio expansion and collaborate with the research and development team to drive in
- Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DMEhttps://modernod.com/news/oculis-accelerates-enrollment-for-phase-3-diamond-trials-of-ocs-01-eye-drops-in-diabetic-macular-edema/2482504/Oculis announced significant progress in patient enrollment for both phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program, designed to assess the efficacy and safety of OCS-01, an investigational eye drop, has enrolled about 70% of patients in the phase